We propose cell and gene therapy trial infrastructure that will focus on hereditary hematological and immunologic disorders and on anti-inflammatory lung disorders. This alpha stem cell clinic operation at UCSF will expand access to these novel cell and gene therapies to California citizens . The objective of this proposal from the Univ. of Calif., San Francisco is to expand the opportunity for California citizens to receive cellular therapies that have curative potential, especially in under-represented populations and diseases. We will accomplish this by giving therapy that can cure hereditary blood disorders, highlighted by a first-in-human, CIRM-funded CRISPR gene editing trial in sickle cell disease, and in treating lung inflammation from trauma and infections such as COVID-19.